Expertise in
34
conditions

Thomas Klopstock

Feodor Lynen Str. 17, 
Munich, BY, DE 
Expertise in
34
conditions
Feodor Lynen Str. 17, 
Munich, BY, DE 

Overview

Thomas Klopstock practices practicing medicine in Munich, Germany.

Mr. Klopstock is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Optic Nerve Atrophy, Leber Hereditary Optic Neuropathy (LHON), Pantothenate Kinase-Associated Neurodegeneration, and Hallervorden-Spatz Disease.

He is actively involved in clinical research, co-authoring 256 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Feodor Lynen Str. 17, Munich, BY 81377, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Biological, Device
Study Phase: Phase 3
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Biological, Device
Study Phase: Phase 3
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Genetic, Other
Study Phase: Phase 3
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Enrollment Status: Completed
Publish Date: October 03, 2025
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: REN001
Study Phase: Phase 2
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
Enrollment Status: Completed
Publish Date: July 16, 2021
Intervention Type: Drug
View 5 Less Clinical Trials

256 Total Publications

Rare hereditary and acquired diseases with parkinson's syndrome
Rare hereditary and acquired diseases with parkinson's syndrome
Journal: Fortschritte der Neurologie-Psychiatrie
Published: July 02, 2026

Frequently Asked Questions about Thomas Klopstock

Is Thomas Klopstock a top-rated expert for Optic Nerve Atrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas Klopstock is classified as an Elite expert for Optic Nerve Atrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas Klopstock participate in research or clinical trials?

Yes. Thomas Klopstock has published 256 articles and abstracts on conditions like Optic Nerve Atrophy. You can view a list of Thomas Klopstock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Klopstock's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 17 Advanced Conditions
View All 61 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile